Sermorelin is a synthetic GHRH fragment studied for pulsatile growth hormone release and somatotropic-axis signaling.
Pre-loaded with a typical Sermorelin vial. Change any value to match what you actually have.
What published research and laboratory protocols actually document for Sermorelin. Where a compound has no single microgram figure, we say so rather than inventing one.
| Reported amount | Frequency | Route | Where this figure comes from |
|---|---|---|---|
| 1.05 mcg – 35 mcg | single bolus in study protocol | intravenous | Normal-volunteer GHRH(1-29)-NH2 bolus study, expressed as approximate 70 kg equivalent Original paper reported 0.015-0.5 mcg/kg; this is reference conversion, not guidance. |
| 17.5 mcg – 140 mcg | single administration in study protocol | intravenous | Healthy-men pharmacokinetic study, approximate 70 kg equivalent Original paper studied 0.25-2 mcg/kg IV and higher intranasal amounts due to low bioavailability. |
| 350 mcg – 3.5 mg | single or repeated study administrations | intranasal | Intranasal research exposure in healthy men, approximate 70 kg equivalent Intranasal bioavailability was reported as low; not comparable to subcutaneous research material. |
People searching this page also look for: sermorelin peptide dosage, sermorelin peptide dosage for men, sermorelin peptide dosage chart, sermorelin peptide dosage for women, peptide sermorelin dosage, sermorelin peptide injection dosage, sermorelin peptide dosage reddit, sermorelin peptide dosage women.
Sermorelin is the 1-29 amino acid fragment of growth hormone-releasing hormone and retains the core biological activity needed to stimulate pituitary GH release in research settings. It has been studied as a diagnostic and investigational endocrine tool, especially where researchers want to evaluate somatotropic-axis responsiveness rather than administer growth hormone directly.
The literature includes intravenous, intranasal, and subcutaneous contexts, with strong attention to GH pulses, IGF-1 changes, pharmacokinetics, and route-dependent bioavailability. Research-grade sermorelin is not an approved drug product for casual use and is commonly labeled Research Use Only. Reported ranges below summarize published study exposure ranges, not recommendations.
Sermorelin binds the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs. Receptor activation increases cAMP signaling and promotes pulsatile growth hormone secretion when pituitary reserve is present. Because the molecule acts upstream of GH release, research readouts often include GH peak, GH area under the curve, IGF-1 changes, and route-dependent absorption. Intranasal bioavailability has been reported as low relative to intravenous administration.
growth hormone secretion · pituitary function · endocrine diagnostics · IGF-1 signaling · GHRH analog pharmacokinetics
Sermorelin is studied by endocrinologists, pediatric growth researchers, pharmacokinetic teams, and anti-doping laboratories. It is also examined by analytical chemists because GHRH analogs require careful detection and identity testing.
Lyophilized sermorelin is commonly kept frozen or refrigerated per supplier specifications, protected from moisture; reconstituted research solutions are generally refrigerated and handled aseptically.
Sermorelin is often discussed with other GH secretagogues, but combined protocols can make GH, IGF-1, glucose, and sleep-related endpoints hard to attribute. Research designs usually control timing, fasting state, and co-administered secretagogues carefully because pituitary response is pulsatile and context-sensitive.
The questions people actually search for, answered plainly.
Published studies report route-specific research exposures, including mcg/kg intravenous and intranasal protocols. These are literature references, not dosing instructions.
Common research reconstitution examples use 1-3 mL for small vials. The volume only changes concentration math; it does not define a recommended amount.
Daily sermorelin discussions usually come from clinical or research protocols with defined endpoints. For education pages, the route, frequency, and population should be kept separate.
A chart should show vial strength, reconstitution volume, concentration, and cited study context. It should not turn literature values into personal-use instructions.
GH response in challenge studies can occur within minutes to hours, while IGF-1 or downstream endocrine readouts require longer study windows.
Sermorelin has a short plasma half-life. Researchers often care more about the GH pulse it triggers than about prolonged peptide exposure.
It can be studied with other secretagogues, but stacking complicates interpretation. Research-only materials are not for human consumption.
Primary literature on Sermorelin. Open access where available.
Every citation above was programmatically checked against the NCBI PubMed database. Titles shown are the official indexed titles, not paraphrases.
Our support assistant walks through reconstitution, syringe units, storage, and how to read a Certificate of Analysis. Free, no account.
Read the guides